Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

• DOI: 10.1016/j.ijchv.2014.03.007
• Publication Date: 2014-03-21T15:44:17Z
• Authors: Muhammad Tariq Sh...; Samia Ayub; Sajid Dhakam
• Keywords: Abciximab; Mace; Bolus (digestion)

Abciximab reduces major adverse cardiac events in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Standard protocol is intravenous abciximab bolus during PCI plus infusion for 12-18 h post pPCI. Intracoronary (IC) administration results high local drug concentrations and hence it should have higher antiplatelet effect. In this study, we assess the short-term efficacy safety of IC compared to IV ACS pPCI.We clinical outcomes between (n = 56) standard 170) group patients. Primary endpoints included bleeding/vascular/ischemic complications MACE.The two groups were similar respect baseline characteristics. only reduced bleeding complications, no moderate bleed versus 7.2% (p value 0.04). Ischemic/vascular had statistically insignificant difference groups.We found significant therapy terms ischemic/vascular MACE. But there was risk group. The route may be superior route. Prospective randomized trials are warranted validate these findings.